Table 2. Subgroup analysis for the association of n-3 LCPUFA intake (high vs. low) and risk of all-cause mortality.
| N | RR (95% CI) | P heterogeneity | I2(%) | Pdifference | |
|---|---|---|---|---|---|
| Overall | 7 | 0.90 (0.83–0.98) | 0.005 | 70.0 | |
| Area | |||||
| Asian | 4 | 0.90 (0.77–1.05) | 0.003 | 82.6 | 0.91 |
| USA | 3 | 0.91 (0.83–0.99) | 0.12 | 53.4 | |
| Duration | |||||
| ≥10 years | 5 | 0.91 (0.81–1.03) | 0.004 | 77.8 | 0.74 |
| <10 years | 2 | 0.88 (0.77–1.01) | 0.08 | 68.2 | |
| Sex | |||||
| Male | 1 | 1.03 (0.86–1.23) | – | – | Ref. |
| Female | 2 | 0.98 (0.90–1.07) | 0.45 | 0 | 0.72 |
| Both | 5 | 0.86 (0.79–0.94) | 0.05 | 62.7 | 0.24 |
| Mean/median age at baseline | |||||
| ≥55 years | 2 | 0.89 (0.76–1.04) | 0.05 | 73.2 | 0.75 |
| <55 years | 5 | 0.92 (0.83–1.01) | 0.01 | 67.8 | |
| Range of intakea | |||||
| ≥0.30 g/d | 4 | 0.91 (0.85–0.97) | 0.22 | 31.4 | 0.14 |
| <0.30 g/d | 2 | 0.79 (0.72–0.87) | –b | –b | |
| Quality scores | |||||
| ≥8 | 5 | 0.91 (0.82–1.01) | 0.005 | 76.8 | 0.84 |
| <8 | 2 | 0.89 (0.76–1.04) | 0.05 | 73.2 | |
| Subtypes | |||||
| EPA | 3 | 0.83 (0.75–0.92) | 0.15 | 51.5 | 0.83 |
| DPA | 3 | 0.81 (0.74–0.90) | 0.20 | 38.5 | |
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCPUFA, long-chain polyunsaturated fatty acids.
aThe mean/median intakes in the highest categories minus those in the lowest categories was the range of intake. This analysis excluded the study by Nagata et al. in which the intake levels for each category were not reported.
bOnly two cohorts from one publication were included in this stratum, and so no result for heterogeneity test were reported here.